Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1311-a-1313-a, 2005; 10.1373/clinchem.2005.048439
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hubacek, J. A.
Right arrow Articles by Vráblík, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hubacek, J. A.
Right arrow Articles by Vráblík, M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:1311-1313.)
© 2005 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Hypertriglyceridemia: Interaction between APOE and APOAV Variants

Jaroslav A. Hubacek1,3,a, Ales Horínek4, Zdena Skodova2, Vera Adamkova2, Richard Ceska4, Lukas Zlatohlavek4 and Michal Vráblík4

1 Centre for Experimental Medicine, and, 2 Department of Preventive Cardiology, Institute of Clinical, and Experimental Medicine, Prague, Czech Republic
3 Cardiovascular Research Centre, Prague, Czech Republic
4 3rd Department of Medicine, 1st School of Medicine, Charles University, Prague, Czech Republic

aAddress correspondence to this author at: IKEM-CEM-LMG, Videnska 1958/9, 140 21 Prague 4, Czech Republic. Fax 420-241-721-574; e-mail jahb@medicon.cz.

The first 20% of the full text of this article appears below.


To the Editor:

Schaefer et al. (1) recently reported an association between a distinct combination of variants in the apolipoprotein E (APOE) and APOAV genes and hypertriglyceridemia. Among 170 hypertriglyceridemic (HTG) patients, all carriers of APOE22 (n = 7) had at least 1 APOAV Trp19 allele, but this combination was not found in controls with triglyceride (TG) concentrations within the reference interval.

APOE is a structural component of TG-rich lipoproteins; it serves as a ligand for lipoprotein receptors and plays an important role in the catabolism of remnant particles (2)(3). Of the 3 common apoE isoforms, apoE4 (Cys112>Arg) and apoE2 (Arg158>Cys) differ from the commonest isoform, apoE3, by a single amino acid substitution. The APOE4 allele has been shown to be associated with increased plasma cholesterol and with an increased risk of coronary heart disease. In contrast, the APOE2 allele is associated with low plasma concentrations of cholesterol and is believed to be protective against coronary . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.